@prefix : <http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix core: <http://purl.obolibrary.org/obo/uberon/core#> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix pato: <http://purl.obolibrary.org/obo/pato#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix core1: <http://purl.obolibrary.org/obo/core#> .
@prefix terms: <http://purl.org/dc/terms/> .
@prefix uberon: <http://purl.obolibrary.org/obo/uberon#> .
@prefix subsets: <http://purl.obolibrary.org/obo/ro/subsets#> .
@prefix oboInOwl: <http://www.geneontology.org/formats/oboInOwl#> .
@prefix OpenPVSignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl#> .
@base <http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion> .

<http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion> rdf:type owl:Ontology ;
                                                                              owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ,
                                                                                          mp: ;
                                                                              rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/255517"^^xsd:anyURI ;
                                                                              rdfs:label "Pazopanib and Pericardial Effusion "^^xsd:Literal ;
                                                                              owl:versionInfo "draft-v0.95-20210614"@en .

#################################################################
#    Annotation properties
#################################################################

###  http://purl.org/dc/elements/1.1/publisher
dc:publisher rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/terms/hasVersion
terms:hasVersion rdf:type owl:AnnotationProperty .


###  http://www.w3.org/2004/02/skos/core#exactMatch
skos:exactMatch rdf:type owl:AnnotationProperty .


###  http://www.w3.org/2004/02/skos/core#inScheme
skos:inScheme rdf:type owl:AnnotationProperty .


###  http://www.w3.org/2004/02/skos/core#notation
skos:notation rdf:type owl:AnnotationProperty .


#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
OpenPVSignal:Free_text_reporting_element rdf:type owl:ObjectProperty .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#DiscussionAndConclusion
:DiscussionAndConclusion rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Conclusion ,
                                  OpenPVSignal:Discussion ;
                         OpenPVSignal:has_content """Case reports in VigiBase suggest that there is a signal for the association of pazopanib and pericardial effusion. Pazopanib was the only drug suspected in all but one of the nine ICSRs. In the report in which there was another suspected drug (Case 4) pericardial effusion was present before pazopanib was commenced so pazopanib is unlikely to be a cause in this case. Two of the other reports have a doubtful association. In Case 1, the reporter considered that pericardial effusion may have been caused by pleural lesions as a consequence of disease progression and the patient died from disease progression soon after. In Case 10, pericardial fluid was present before treatment commenced but there was increased fluid in association with pazopanib.


Time to onset is not particularly suggestive of a signal. In the six reports in which causality is plausible, the time to onset ranged from eight weeks to six months which appears rather long for

a	drug-induced effect. However, pericardial effusion may be present without symptoms so it is possible that the time to onset was shorter than reported.

Dechallenge is also possibly suggestive of a signal. In the six reports in which causality is plausible, the out¬come was stated in four reports. The patients were reported as recovered in three cases of these four and not recovered in the other case. In all of the six cases, the drug was reported to have been withdrawn. Importantly, in two cases the reaction recurred on rechallenge.

In the literature, pericardial effusion was reported to occur in 3% of Asian patients in a Phase II trial of pazopanib with recurrent/metastatic undifferentiated nasopharyngeal carcinoma. In addition, it has been noted that other TKI such as nilotinib and dasatinib are known to be associated with pericardial effusion. Moreover, pericardial effusion is reported as an adverse effect in the product information of other TKIs including imatinib, nilotinib and dasatinib.

In VigiBase, there have been 5651 occurrences of pericardial effusion. Only 13 drugs have a hundred or more reports of the association and two of these are the TKIs dasatinib (120) and imatinib (107). In addition, there are many reports with erlotinib (66), sunitinib (49), nilotinib (21), sorafenib (17) and gefitinib (14) and it seems likely that pericardial effusion is a class effect of TKIs.
""" ;
                         rdfs:label "Discussion and conclusion" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#DrIanBoyd
:DrIanBoyd rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Author ;
           OpenPVSignal:has_affiliation "Australia" ;
           OpenPVSignal:has_first_name "Ian" ;
           OpenPVSignal:has_last_name "Boyd" ;
           rdfs:label "Dr Ian Boyd" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#IC025ForPazopanibAndPericardialEffusion
:IC025ForPazopanibAndPericardialEffusion rdf:type owl:NamedIndividual ,
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                         OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
                                         OpenPVSignal:refers_to_drug :pazopanib ;
                                         OpenPVSignal:refers_to_information_component :ICForPazopanibAndPericardialEffusion ;
                                         OpenPVSignal:has_value 1.68 ;
                                         OpenPVSignal:refers_to_number_of_reports 11 ;
                                         rdfs:label "IC025 for pazopanib and pericardial effusion" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#ICForPazopanibAndPericardialEffusion
:ICForPazopanibAndPericardialEffusion rdf:type owl:NamedIndividual ,
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                                      OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
                                      OpenPVSignal:refers_to_drug :pazopanib ;
                                      OpenPVSignal:has_value 2.65 ;
                                      OpenPVSignal:refers_to_number_of_reports 11 ;
                                      rdfs:label "IC for pazopanib and pericardial effusion" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#LiteratureAndLabelling
:LiteratureAndLabelling rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Literature_information ;
                        mp:references :Ref.4 ,
                                      :Ref.5 ;
                        OpenPVSignal:has_content "The product literature does not refer to pericardial effusion. There is a warning on the possibility of cardiac dysfunction such as congestive heart failure and decreased left ventricular function. Such cardiac dysfunction could result in the development of pericardial effusion but as none of the reports document these other cardiac reactions, this does not appear to be a cause. In the literature, pericardial effusion was repor¬ted to occur in 3% of Asian patients in a Phase II trial of pazopanib with recurrent/metastatic undifferen-tiated nasopharyngeal carcinoma.4 In addition, it has been noted that other tyrosine kinase inhibitors such as nilotinib and dasatinib are known to be associated with pericardial effusion.5 Moreover, pericardial effusion is reported as an adverse effect in the product informa¬tion of other TKIs including imatinib, nilotinib and dasatinib." ;
                        rdfs:label "Literature and Labelling" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#MechanismOfPazopanib
:MechanismOfPazopanib rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Mechanism ;
                      OpenPVSignal:has_content "Pazopanib is an orally administered, potent multi-target tyrosine kinase inhibitor (TKI) of Vascular Endothelial Growth Factor Receptors (VEGFR)-1, - 2, and -3, platelet-derived growth factor (PDGFR)- α and -β, and stem cell factor receptor (c-KIT). It is indicated for the first line treatment of advanced renal cell carcinoma (RCC) and the treatment of selective subtypes of advanced soft tissue sarcoma (STS)." ;
                      rdfs:label "Mechanism of Pazopanib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Oral_administration
:Oral_administration rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Drug_Intake_Form ;
                     OpenPVSignal:refers_to_drug :pazopanib ;
                     OpenPVSignal:refers_to_form_of_intake "oral" ;
                     rdfs:label "Oral administration" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Patient1
:Patient1 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 75 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Patient10
:Patient10 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 30 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 10" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Patient11
:Patient11 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 44 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 11" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Patient2
:Patient2 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 50 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Patient3
:Patient3 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 77 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Patient4
:Patient4 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 21 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Patient5
:Patient5 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 39 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Patient6
:Patient6 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 80 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Patient7
:Patient7 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 42 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Patient8
:Patient8 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 42 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 8" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Patient9
:Patient9 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 42 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 9" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#PazopanibAndPericardialEffusion
:PazopanibAndPericardialEffusion rdf:type owl:NamedIndividual ,
                                          OpenPVSignal:Pharmacovigilance_Signal_Report ;
                                 OpenPVSignal:refers_to_author :DrIanBoyd ;
                                 OpenPVSignal:refers_to_signal :pvSignal ;
                                 mp:publishedBy :Uppsala_Monitoring_Centre ;
                                 OpenPVSignal:has_creation_date "01/12/13" ;
                                 OpenPVSignal:has_overall_conclusion "causal association" ;
                                 rdfs:label "Pazopanib and Pericardial Effusion" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#PericardialEffusion
:PericardialEffusion rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Free_text_reporting_element ;
                     OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
                     mp:references :Ref.2 ,
                                   :Ref.3 ;
                     OpenPVSignal:has_content """Pericardial effusion is the accumulation of fluid in excess of normal in the pericardial cavity. It can be confirmed by the demonstration of fluid in the pericardial cavity by echocardiography. Pericardial effusion may present in either acute or chronic form. It may be the first sign of acute pericarditis. It may also occur in heart failure and cardiomyopathy of various types, and in myxoedema.2 The cause of abnormal fluid production depends on the underlying aetiology, but it is usually secondary to injury or insult to the pericardium (that is, pericarditis). Transudative fluids result from obstruction of fluid drainage, which occurs through lymphatic channels. Exudative fluids occur secondary to inflammatory, infectious, malignant, or autoimmune processes within the pericardium.3 The fluid may be serious, serofibrinous, serosanguineous or chylous.2


Signs and symptoms of pericardial effusion include chest pain, pressure or discomfort, light-headedness or syncope, palpitations, cough, dyspnoea, hoarseness, anxiety and confusion, and hiccoughs.3 Examination findings in patients with pericardial effusion include the classic Beck triad of pericardial tamponade: hypotension, muffled heart sounds and jugular venous distention. Other examination findings include pulsus paradoxus, pericardial friction rub, tachycardia, hepatojugular reflux, tachypnoea, decreased breath sounds, Ewart sign (dullness to percussion beneath the angle of left scapula), hepatosplenomegaly, weakened peripheral pulses, edema, and cyanosis.3


As an adverse drug reaction it occurs relatively commonly in drug-induced systemic lupus erythematosus; it may also occur as an immunological reaction to a drug.2""" ;
                     rdfs:label "Pericardial effusion pathophysiology" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Phase_2_trial
:Phase_2_trial rdf:type owl:NamedIndividual ,
                        obo:OAE_0001197 ,
                        OpenPVSignal:Clinical_trial_information ;
               OpenPVSignal:concerns_indication_for_use :undifferentiatedNasopharyngealCarcinoma ;
               OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
               OpenPVSignal:refers_to_drug :pazopanib ;
               mp:references :Ref.4 ;
               OpenPVSignal:has_content "In the literature, pericardial effusion was reported to occur in 3% of Asian patients in a Phase II trial of pazopanib with recurrent/metastatic undifferentiated nasopharyngeal carcinoma.4" ;
               rdfs:label "Phase 2 trial" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Protein_kinase_inhibitors
:Protein_kinase_inhibitors rdf:type owl:NamedIndividual ,
                                    OpenPVSignal:DrugClass ;
                           OpenPVSignal:has_ATC_code "L01E" ;
                           rdfs:label "Protein kinase inhibitors" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Ref.1
:Ref.1 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "European Medicines Agency Summary of Product Characteristics for pazopanib (Votnent). URL: http:// www.ema.europa.eu/docs/en_GB/document_librar y/ EPAR_-Product_Information/human/001141/ WC500094272.pdf. Accessed: 23 April 2013." ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Ref.2
:Ref.2 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content """The Council for International Organizations of Medical Sciences (CIOMS). Reporting Adverse Drug Reactions: Definitions of Terms and Criteria
for their Use. CIOMS, Geneva, 1999. URL: http://www.cioms.ch/publications/reporting_adverse_drug.pdf/accessed 23 April 2013.""" ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Ref.3
:Ref.3 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Stnmel WJ, Ayub B, Contractor T, authors, Fredi JL, editor. Pericardial Effusion. Medscape Reference: Drugs, Diseases and Procedures. URL: http://emedicine.medscape.com/article/157325-overview#aw2aab6b2b3aa. Accessed: 23 April 2013." ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Ref.4
:Ref.4 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Lim WT, Thng C, Toh CK. A phase II study of GW786034 (pazopanib) in Asian patients with recurrent/metastatic undifferentiated nasopharyngeal carcinoma. J Clin Oncol. 2010;28:5556." ;
       rdfs:label "Ref.4" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Ref.5
:Ref.5 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Escalante CP, Zalpour A. Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. Cardiol Res Pract 2011; doi:10.4061/2011/816897." ;
       rdfs:label "Ref.5" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#RenalCellCarcinoma
:RenalCellCarcinoma rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Indication ;
                    OpenPVSignal:has_ICD_code "C64.9" ;
                    OpenPVSignal:has_MedDRA_code 10067946 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Renal cell carcinoma" ;
                    rdfs:label "Renal cell carcinoma" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#ReportsFromGermany
:ReportsFromGermany rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Reports_group ;
                    OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                    OpenPVSignal:has_count 4 ;
                    OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Germany" ;
                    OpenPVSignal:refers_to_database "WHO Vigibase" ;
                    rdfs:label "Reports from Germany" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#ReportsFromGreece
:ReportsFromGreece rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Reports_group ;
                   OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                   OpenPVSignal:has_count 1 ;
                   OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Greece" ;
                   OpenPVSignal:refers_to_database "WHO Vigibase" ;
                   rdfs:label "Reports from Greece" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#ReportsFromIreland
:ReportsFromIreland rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Reports_group ;
                    OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                    OpenPVSignal:has_count 1 ;
                    OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_Kingdom" ;
                    OpenPVSignal:refers_to_database "WHO Vigibase" ;
                    rdfs:label "Reports from Ireland" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#ReportsFromSingapore
:ReportsFromSingapore rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Reports_group ;
                      OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                      OpenPVSignal:has_count 1 ;
                      OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Singapore" ;
                      OpenPVSignal:refers_to_database "WHO Vigibase" ;
                      rdfs:label "Reports from Singapore" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#ReportsFromUnitedStates
:ReportsFromUnitedStates rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Reports_group ;
                         OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                         OpenPVSignal:has_count 4 ;
                         OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_States" ;
                         OpenPVSignal:refers_to_database "WHO Vigibase" ;
                         rdfs:label "Reports from United States" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#ReportsInVigiBase
:ReportsInVigiBase rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Free_text_reporting_element ;
                   OpenPVSignal:has_content """As of 25 January 2013 there are 11 Individual Case Safety Reports (ICSRs) of pericardial effusion in association with pazopanib in the WHO Global ICSR Database, VigiBase™ (Table 1). The association has an IC value of 2.65 with an IC025 value of 1.68. The ICSRs were submitted from Germany, the United States (four cases each), Greece, Ireland and Singapore (one case each). After the removal of two suspected duplicates from the US, the patients ranged in age from 21 to 80 years with a median of 44 years. The gender distribu¬tion was five females and four males.
Pazopanib was the only drug suspected in all but one of the nine cases. The other suspected drug was moxifloxacin. Concomitant drugs were reported in four cases but there was little pattern in these reports apart from the use of antihypertensives (in three cases), proton pump inhibitors (two cases) and NSAIDs (two cases). Pazopanib was reported to have been administered orally, as expected, in all eight cases which provided this information. The indication for use was clearly stated in seven reports and included treatment of sarcoma (three cases), metastatic renal cell carcinoma (three cases) and malignant lung neoplasm (one case).
Time to onset was reported in six of the reports. It ranged from eight weeks to six months with a median of four months in five cases but in the other case (Case 4) pericardial effusion was present before pazopanib was commenced so pazopanib is unlikely to be a cause in this case. Two of the other reports have a doubtful association. In Case 1, the reporter considered that pericardial effusion may have been caused by pleural lesions as a consequence of disease progression and the patient died from disease progression soon after. In Case 10, pericardial fluid was present before treatment commenced but there was increased fluid in association with pazopanib. Removal of Case 1, 4 and 10 from the assessment results in six cases with a plausible association.


The outcome was stated in seven ICSRs. The patients were reported as recovered or recovering in four cases, not recovered in two cases and the outcome was fatal in the remaining case although the outcome of the pericardial effusion was unknown. In all of these cases, the drug was reported to have been withdrawn. In two of these cases (Case 5 and 7), the reaction recurred on rechallenge. The drug was also withdrawn in the two cases where the outcome remains unknown.

Other reactions were described in six reports. In general, these reactions appeared indicative of a patient population with severe disease and included abnormal hepatic function (three cases), pleural effusion, cardiac tamponade and fatigue (each in two cases).""" ;
                   rdfs:label "Reports in VigiBase" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Reports_with_pericardial_effusion_and_erlotinib
:Reports_with_pericardial_effusion_and_erlotinib rdf:type owl:NamedIndividual ,
                                                          OpenPVSignal:Reports_group ;
                                                 OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
                                                 OpenPVSignal:refers_to_drug :erlotinib ;
                                                 OpenPVSignal:has_count 66 ;
                                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                 rdfs:label "Reports with pericardial effusion and erlotinib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Reports_with_pericardial_effusion_and_gefitinib
:Reports_with_pericardial_effusion_and_gefitinib rdf:type owl:NamedIndividual ,
                                                          OpenPVSignal:Reports_group ;
                                                 OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
                                                 OpenPVSignal:refers_to_drug :gefitinib ;
                                                 OpenPVSignal:has_count 14 ;
                                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                 rdfs:label "Reports with pericardial effusion and gefitinib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Reports_with_pericardial_effusion_and_imatinib
:Reports_with_pericardial_effusion_and_imatinib rdf:type owl:NamedIndividual ,
                                                         OpenPVSignal:Reports_group ;
                                                OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
                                                OpenPVSignal:refers_to_drug :imatinib ;
                                                OpenPVSignal:has_count 107 ;
                                                OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                rdfs:label "Reports with pericardial effusion and imatinib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Reports_with_pericardial_effusion_and_nilotinib
:Reports_with_pericardial_effusion_and_nilotinib rdf:type owl:NamedIndividual ,
                                                          OpenPVSignal:Reports_group ;
                                                 OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
                                                 OpenPVSignal:refers_to_drug :nilotinib ;
                                                 OpenPVSignal:has_count 21 ;
                                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                 rdfs:label "Reports with pericardial effusion and nilotinib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Reports_with_pericardial_effusion_and_sorafenib
:Reports_with_pericardial_effusion_and_sorafenib rdf:type owl:NamedIndividual ,
                                                          OpenPVSignal:Reports_group ;
                                                 OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
                                                 OpenPVSignal:refers_to_drug :sorafenib ;
                                                 OpenPVSignal:has_count 17 ;
                                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                 rdfs:label "Reports with pericardial effusion and sorafenib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Reports_with_pericardial_effusion_and_sunitinib
:Reports_with_pericardial_effusion_and_sunitinib rdf:type owl:NamedIndividual ,
                                                          OpenPVSignal:Reports_group ;
                                                 OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
                                                 OpenPVSignal:refers_to_drug :sunitinib ;
                                                 OpenPVSignal:has_count 49 ;
                                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                 rdfs:label "Reports with pericardial effusion and sunitinib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Reports_with_pericardial_effussion_and_dasatinib
:Reports_with_pericardial_effussion_and_dasatinib rdf:type owl:NamedIndividual ,
                                                           OpenPVSignal:Reports_group ;
                                                  OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
                                                  OpenPVSignal:refers_to_drug :dasatinib ;
                                                  OpenPVSignal:has_count 120 ;
                                                  OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                  rdfs:label "Reports with pericardial effusion and dasatinib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#SoftTissueSarcoma
:SoftTissueSarcoma rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Indication ;
                   OpenPVSignal:has_ICD_code "C49.9" ;
                   OpenPVSignal:has_MedDRA_code 10075333 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Soft tissue sarcoma" ;
                   rdfs:label "Soft tissue sarcoma" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#SummaryContent
:SummaryContent rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Summary ;
                OpenPVSignal:has_content """Summary

Pazopanib is an orally administered, potent multi-target tyrosine kinase inhibitor (TKI) of Vascular Endothelial Growth Factor Receptors. It is indicated for the first line treatment of advanced renal cell carcinoma (RCC) and the treatment of selective subtypes of advanced soft tissue sarcoma (STS). In the WHO Global Individual Case Safety Report (ICSR) Database, VigiBaseTM, there are currently (25 January 2013) 11 ICSRs of pericardial effusion in association with pazopanib. The ICSRs are from the United States, Germany, Greece, Ireland and Singapore. The association has an IC value of 2.65 with an IC025 value of

1.68. There are two probable duplicates, which leaves a total of nine ICSRs. Pazopanib was the only drug suspected in all but one. The outcome was stated in seven ICSRs. The patients were reported as recovered or recovering in four cases, not recovered in two cases and the outcome was fatal in one case. In all of these cases, the drug was reported to have been withdrawn. In two of the cases, the reaction recurred on rechallenge.

The association of pericardial effusion with pazopanib appears to be a signal. Pazopanib was the only drug suspected in eight of the nine cases and causality is plausible in six cases. While the time to onset is not particularly suggestive of a drug-induced effect, the observation of recovery after dechallenge in the three cases in which recovery was documented, is also supportive of the signal. In addition, the fact that the reaction recurred on rechallenge in two cases is strongly suggestive. A report in the literature indicated that pericardial effusion occurred in 3% of patients in a clinical trial and the observation that pericardial effusion is associated with other TKIs points to the fact that pericardial effusion may be a class effect of TKIs. Reports of pericardial effusion in VigiBase support this proposition.""" ;
                rdfs:label "Summary content" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#TKIsTriggeringPericardialEffusion
:TKIsTriggeringPericardialEffusion rdf:type owl:NamedIndividual ,
                                            obo:OAE_0001197 ;
                                   OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
                                   OpenPVSignal:refers_to_drug :dasatinib ,
                                                               :nilotinib ;
                                   mp:references :Ref.5 ;
                                   OpenPVSignal:has_content "In addition, it has been noted that other tyrosine kinase inhibitors such as nilotinib and dasatinib are known to be associated with pericardial effusion.5 Moreover, pericardial effusion is reported as an adverse effect in the product informa¬tion of other TKIs including imatinib, nilotinib and dasatinib." ;
                                   rdfs:label "TKIs triggering pericardial effusion" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Uppsala_Monitoring_Centre
:Uppsala_Monitoring_Centre rdf:type owl:NamedIndividual ,
                                    prov:Organization ;
                           rdfs:label "Uppsala Monitoring Centre" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#UsageOfPazopanib
:UsageOfPazopanib rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Drug_Usage ;
                  OpenPVSignal:concerns_indication_for_use :RenalCellCarcinoma ,
                                                           :SoftTissueSarcoma ;
                  OpenPVSignal:refers_to_drug :pazopanib ;
                  rdfs:label "Usage of Pazopanib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Warning_information_for_pazopanib
:Warning_information_for_pazopanib rdf:type owl:NamedIndividual ,
                                            OpenPVSignal:Warning_Information ;
                                   OpenPVSignal:refers_to_drug :pazopanib ;
                                   OpenPVSignal:refers_to_known_adverse_effect :abnormalHepaticFunction ,
                                                                               :anorexia ,
                                                                               :cardiacDysfunction ,
                                                                               :cerebralHaemorrhage ,
                                                                               :cerebralInfarction ,
                                                                               :diarrhoea ,
                                                                               :dysgeusia ,
                                                                               :elevatedAlanineAminotransferase ,
                                                                               :elevatedAspartateAminotransferase ,
                                                                               :exfoliativeRash ,
                                                                               :fatigue ,
                                                                               :fistula ,
                                                                               :gastrointestinalHaemorrhage ,
                                                                               :gastrointestinalPerforation ,
                                                                               :hairColourChange ,
                                                                               :headache ,
                                                                               :hemoptysis ,
                                                                               :hypertension ,
                                                                               :intestinalPerforation ,
                                                                               :ischaemicStroke ,
                                                                               :leftVentricularDysfunction ,
                                                                               :myocardialInfarction ,
                                                                               :myocardialIschaemia ,
                                                                               :nausea ,
                                                                               :pain ,
                                                                               :pneumothorax ,
                                                                               :pulmonaryHemorrhage ,
                                                                               :qtProlongation ,
                                                                               :skinHypopigmentation ,
                                                                               :stomatitis ,
                                                                               :transientIschaemicAttack ,
                                                                               :venousThromboembolicEvents ,
                                                                               :vomiting ,
                                                                               :weightDecreased ;
                                   mp:references :Ref.1 ;
                                   OpenPVSignal:has_content "The most common adverse reactions (experienced by at least 10% of the patients) of any grade in the RCC and STS trials included: diarrhoea, hair colour change, skin hypopigmentation, exfoliative rash, hypertension, nausea, headache, fatigue, anorexia, vomiting, dysgeusia, stomatitis, weight decreased, pain, elevated alanine aminotransferase and elevated aspartate aminotransferase. The most important serious adverse reactions identified in the RCC or STS trials were transient ischaemic attack, ischaemic stroke, myocardial ischaemia, myocardial and cerebral infarction, cardiac dysfunction, gastrointestinal perforation and fistula, QT prolongation and pulmonary, gastrointestinal and cerebral haemorrhage, all adverse reactions being reported in <1% of treated patients. Other important serious adverse reactions identified in STS trials included venous thromboembolic events, left ventricular dysfunction and pneumothorax. Fatal events that were considered possibly related to pazopanib included gastrointestinal haemorrhage, pulmonary haemorrhage/haemoptysis, abnormal hepatic function, intestinal perforation and ischemic stroke.1" ;
                                   rdfs:label "Warning information for pazopanib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#Warning_on_the_possibility_of_cardiac_dysfunction
:Warning_on_the_possibility_of_cardiac_dysfunction rdf:type owl:NamedIndividual ,
                                                            obo:OAE_0001197 ,
                                                            OpenPVSignal:Warning_Information ;
                                                   OpenPVSignal:refers_to_adverse_effect :cardiacDysfunction ,
                                                                                         :congestiveHeartFailure ,
                                                                                         :leftVentricularDysfunction ;
                                                   OpenPVSignal:refers_to_drug :pazopanib ;
                                                   OpenPVSignal:has_content "There is a warning on the possibility of cardiac dysfunction such as congestive heart failure and decreased left ventricular function. Such cardiac dysfunction could result in the development of pericardial effusion but as none of the reports document these other cardiac reactions, this does not appear to be a cause." ;
                                                   rdfs:label "Warning on the possibility of cardiac dysfunction" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#abnormalHepaticFunction
:abnormalHepaticFunction rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Adverse_Effect ;
                         OpenPVSignal:has_ICD_code "R94.5" ;
                         OpenPVSignal:has_MedDRA_code 10019670 ;
                         OpenPVSignal:has_MedDRA_prefered_term "Hepatic function abnormal" ;
                         rdfs:label "abnormal hepatic function" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#amlodipine
:amlodipine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "C08CA01" ,
                                      "C08GA02" ,
                                      "C09BB03" ,
                                      "C09BB04" ,
                                      "C09BB07" ,
                                      "C09BX01" ,
                                      "C09DB01" ,
                                      "C09DB02" ,
                                      "C09DB04" ,
                                      "C09DB05" ,
                                      "C09DB06" ,
                                      "C09DB07" ,
                                      "C09DX01" ,
                                      "C09DX03" ,
                                      "C09XA53" ,
                                      "C09XA54" ,
                                      "C10BX03" ,
                                      "C10BX07" ,
                                      "C10BX09" ,
                                      "C10BX11" ;
            rdfs:label "amlodipine" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#anorexia
:anorexia rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "R63.0" ;
          OpenPVSignal:has_MedDRA_code 10061428 ;
          OpenPVSignal:has_MedDRA_prefered_term "Decreased appetite" ;
          rdfs:label "anorexia" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#cardiacDysfunction
:cardiacDysfunction rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_ICD_code "I51.9" ;
                    OpenPVSignal:has_MedDRA_code 10079751 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Cardiac dysfunction" ;
                    rdfs:label "cardiac dysfunction" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#cardiacTamponade
:cardiacTamponade rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_ICD_code "I31.4" ;
                  OpenPVSignal:has_MedDRA_code 10007610 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Cardiac tamponade" ;
                  rdfs:label "cardiac tamponade" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#cardiomegaly
:cardiomegaly rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "I51.7" ;
              OpenPVSignal:has_MedDRA_code 10007632 ;
              OpenPVSignal:has_MedDRA_prefered_term "Cardiomegaly" ;
              rdfs:label "cardiomegaly" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#carvedilol
:carvedilol rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "C07AG02" ;
            rdfs:label "carvedilol" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#cerebralHaemorrhage
:cerebralHaemorrhage rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "I62.9" ;
                     OpenPVSignal:has_MedDRA_code 10008111 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Cerebral haemorrhage" ;
                     rdfs:label "cerebral haemorrhage" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#cerebralInfarction
:cerebralInfarction rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_ICD_code "I63.9" ;
                    OpenPVSignal:has_MedDRA_code 10008118 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Cerebral infarction" ;
                    rdfs:label "cerebral infarction" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#congestiveHeartFailure
:congestiveHeartFailure rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Adverse_Effect ;
                        OpenPVSignal:has_ICD_code "I50.9" ;
                        OpenPVSignal:has_MedDRA_code 10007559 ;
                        OpenPVSignal:has_MedDRA_prefered_term "Cardiac failure congestive" ;
                        rdfs:label "congestive heart failure" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#dasatinib
:dasatinib rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:hasClass :Protein_kinase_inhibitors ;
           OpenPVSignal:has_ATC_code "L01XE06" ;
           rdfs:label "dasatinib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#dexamethasone
:dexamethasone rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "A01AC02" ,
                                         "C05AA09" ,
                                         "D07AB19" ,
                                         "D07CB04" ,
                                         "D07XB05" ,
                                         "D10AA03" ,
                                         "H02AB02" ,
                                         "R01AD03" ,
                                         "R01AD53" ,
                                         "S01BA01" ,
                                         "S01CA01" ,
                                         "S01CB01" ,
                                         "S02BA06" ,
                                         "S02CA06" ,
                                         "S03BA01" ,
                                         "S03CA01" ;
               rdfs:label "dexamethasone" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#diarrhoea
:diarrhoea rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "R19.7" ;
           OpenPVSignal:has_MedDRA_code 10012735 ;
           OpenPVSignal:has_MedDRA_prefered_term "Diarrhoea" ;
           rdfs:label "diarrhoea" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#diseaseRecurrence
:diseaseRecurrence rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ;
                   OpenPVSignal:has_ICD_code "N02.6" ;
                   OpenPVSignal:has_MedDRA_code 10061819 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Disease recurrence" ;
                   rdfs:label "disease recurrence" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#docusate
:docusate rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_ATC_code "A06AA02" ;
          rdfs:label "docusate" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#dysgeusia
:dysgeusia rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "R43.2" ;
           OpenPVSignal:has_MedDRA_code 10013911 ;
           OpenPVSignal:has_MedDRA_prefered_term "Dysgeusia" ;
           rdfs:label "dysgeusia" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#effusion
:effusion rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "J90" ;
          OpenPVSignal:has_MedDRA_code 10063045 ;
          OpenPVSignal:has_MedDRA_prefered_term "Effusion" ;
          rdfs:label "effusion" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#elevatedAlanineAminotransferase
:elevatedAlanineAminotransferase rdf:type owl:NamedIndividual ,
                                          OpenPVSignal:Adverse_Effect ;
                                 OpenPVSignal:has_ICD_code "R74.0" ;
                                 OpenPVSignal:has_MedDRA_code 10001551 ;
                                 OpenPVSignal:has_MedDRA_prefered_term "Alanine aminotransferase increased" ;
                                 rdfs:label "elevated alanine aminotransferase" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#elevatedAspartateAminotransferase
:elevatedAspartateAminotransferase rdf:type owl:NamedIndividual ,
                                            OpenPVSignal:Adverse_Effect ;
                                   OpenPVSignal:has_ICD_code "R74.0" ;
                                   OpenPVSignal:has_MedDRA_code 10003476 ;
                                   OpenPVSignal:has_MedDRA_prefered_term "Aspartate aminotransferase" ;
                                   rdfs:label "elevated aspartate aminotransferase" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#erlotinib
:erlotinib rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "L01XE03" ;
           rdfs:label "erlotinib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#exfoliativeRash
:exfoliativeRash rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_ICD_code "L26" ;
                 OpenPVSignal:has_MedDRA_code 10064579 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Exfoliative rash" ;
                 rdfs:label "exfoliative rash" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#fatigue
:fatigue rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_ICD_code "R53" ;
         OpenPVSignal:has_MedDRA_code 10016256 ;
         OpenPVSignal:has_MedDRA_prefered_term "Fatigue" ;
         rdfs:label "fatigue" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#fistula
:fistula rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_ICD_code "K63.2" ;
         OpenPVSignal:has_MedDRA_code 10016717 ;
         OpenPVSignal:has_MedDRA_prefered_term "Fistula" ;
         rdfs:label "fistula" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#gastrointestinalHaemorrhage
:gastrointestinalHaemorrhage rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Adverse_Effect ;
                             OpenPVSignal:has_ICD_code "K92.2" ;
                             OpenPVSignal:has_MedDRA_code 10017955 ;
                             OpenPVSignal:has_MedDRA_prefered_term "Gastrointestinal haemorrhage" ;
                             rdfs:label "gastrointestinal haemorrhage" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#gastrointestinalPerforation
:gastrointestinalPerforation rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Adverse_Effect ;
                             OpenPVSignal:has_ICD_code "K63.1" ;
                             OpenPVSignal:has_MedDRA_code 10018001 ;
                             OpenPVSignal:has_MedDRA_prefered_term "Gastrointestinal perforation" ;
                             rdfs:label "gastrointestinal perforation" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#gefitinib
:gefitinib rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "L01XE02" ;
           rdfs:label "gefitinib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#glimepiride
:glimepiride rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "A10BB12" ,
                                       "A10BD04" ,
                                       "A10BD06" ;
             rdfs:label "glimepiride" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#hairColourChange
:hairColourChange rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_ICD_code "L67.8" ;
                  OpenPVSignal:has_MedDRA_code 10019030 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Hair colour changes" ;
                  rdfs:label "hair colour change" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#headache
:headache rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "R51" ;
          OpenPVSignal:has_MedDRA_code 10019211 ;
          OpenPVSignal:has_MedDRA_prefered_term "Headache" ;
          rdfs:label "headache" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#hemoptysis
:hemoptysis rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_ICD_code "R04.2" ;
            OpenPVSignal:has_MedDRA_code 10018964 ;
            OpenPVSignal:has_MedDRA_prefered_term "Haemoptysis" ;
            rdfs:label "hemoptysis" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#hepaticEnzymesIncreased
:hepaticEnzymesIncreased rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Adverse_Effect ;
                         OpenPVSignal:has_ICD_code "R94.5" ;
                         OpenPVSignal:has_MedDRA_code 10060795 ;
                         OpenPVSignal:has_MedDRA_prefered_term "Hepatic enzyme increased" ;
                         rdfs:label "hepatic enzymes increased" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#hepaticFailure
:hepaticFailure rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_ICD_code "K72" ;
                OpenPVSignal:has_MedDRA_code 10019663 ;
                OpenPVSignal:has_MedDRA_prefered_term "Hepatic failure" ;
                rdfs:label "hepatic failure" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#hepaticFunctionAbnormal
:hepaticFunctionAbnormal rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Adverse_Effect ;
                         OpenPVSignal:has_MedDRA_code 10019670 ;
                         OpenPVSignal:has_MedDRA_prefered_term "Hepatic function abnormal" ;
                         rdfs:label "hepatic function abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#hepatorenalSyndrome
:hepatorenalSyndrome rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "K76.7" ;
                     OpenPVSignal:has_MedDRA_code 10019846 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Hepatorenal syndrome" ;
                     rdfs:label "hepatorenal syndrome" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#hydromorphone
:hydromorphone rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "N02AA03" ,
                                         "N02AG04" ;
               rdfs:label "hydromorphone" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#hypertension
:hypertension rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "I10" ;
              OpenPVSignal:has_MedDRA_code 10020772 ;
              OpenPVSignal:has_MedDRA_prefered_term "Hypertension" ;
              rdfs:label "hypertension" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#hypotension
:hypotension rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_ICD_code "I95.9" ;
             OpenPVSignal:has_MedDRA_code 10021097 ;
             OpenPVSignal:has_MedDRA_prefered_term "Hypotension" ;
             rdfs:label "hypotension" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#ibuprofen
:ibuprofen rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "C01EB16" ,
                                     "G02CC01" ,
                                     "M01AE01" ,
                                     "M01AE51" ,
                                     "M02AA13" ,
                                     "R02AX02" ;
           rdfs:label "ibuprofen" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#imatinib
:imatinib rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:hasClass :Protein_kinase_inhibitors ;
          OpenPVSignal:has_ATC_code "L01XE01" ;
          rdfs:label "imatinib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#infoForCase1
:infoForCase1 rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Case_Report_Information ;
              OpenPVSignal:has_content "In Case 1, the reporter considered that pericardial effusion may have been caused by pleural lesions as a consequence of disease progression and the patient died from disease progression soon after" ;
              rdfs:label "info for case 1" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#infoForCase10
:infoForCase10 rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Case_Report_Information ;
               OpenPVSignal:has_content "In Case 10, pericardial fluid was present before treatment commenced but there was increased fluid in association with pazopanib." ;
               rdfs:label "info for case 10" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#infoForCase4
:infoForCase4 rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Case_Report_Information ;
              OpenPVSignal:has_content "pericardial effusion was present before pazopanib was commenced so pazopanib is unlikely to be a cause in this case" ;
              rdfs:label "info for case 4" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#intestinalPerforation
:intestinalPerforation rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Adverse_Effect ;
                       OpenPVSignal:has_ICD_code "K63.1" ;
                       OpenPVSignal:has_MedDRA_code 10022694 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Intestinal perforation" ;
                       rdfs:label "intestinal perforation" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#introductionContent
:introductionContent rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Introduction ;
                     mp:references :Ref.1 ,
                                   :Ref.2 ,
                                   :Ref.3 ;
                     OpenPVSignal:has_content """Pazopanib is an orally administered, potent multi-target tyrosine kinase inhibitor (TKI) of Vascular Endothelial Growth Factor Receptors (VEGFR)-1, - 2, and -3, platelet-derived growth factor (PDGFR)-α and -β, and stem cell factor receptor (c-KIT). It is indicated for the first line treatment of advanced renal cell carcinoma (RCC) and the treatment of selective subtypes of advanced soft tissue sarcoma (STS). The most common adverse reactions (experienced by at least 10% of the patients) of any grade in the RCC and STS trials included: diarrhoea, hair colour change, skin hypopigmentation, exfoliative rash, hypertension, nausea, headache, fatigue, anorexia, vomiting, dysgeusia, stomatitis, weight decreased, pain, elevated alanine aminotransferase and elevated aspartate aminotransferase. The most important serious adverse reactions identified in the RCC or STS trials were transient ischaemic attack, ischaemic stroke, myocardial ischaemia, myocardial and cerebral infarction, cardiac dysfunction, gastrointestinal perforation and fistula, QT prolongation and pulmonary, gastrointestinal and cerebral haemorrhage, all adverse reactions being reported in <1% of treated patients. Other important serious adverse reactions identified in STS trials included venous thromboembolic events, left ventricular dysfunction and pneumothorax. Fatal events that were considered possibly related to pazopanib included gastrointestinal haemorrhage, pulmonary haemorrhage/haemoptysis, abnormal hepatic function, intestinal perforation and ischemic stroke.1
Pericardial effusion is the accumulation of fluid in excess of normal in the pericardial cavity. It can be confirmed by the demonstration of fluid in the pericardial cavity by echocardiography. Pericardial effusion may present in either acute or chronic form. It may be the first sign of acute pericarditis. It may also occur in heart failure and cardiomyopathy of various types, and in myxoedema.2 The cause of abnormal fluid production depends on the underlying aetiology, but it is usually secondary to injury or insult to the pericardium (that is, pericarditis). Transudative fluids result from obstruction of fluid drainage, which occurs through lymphatic channels. Exudative fluids occur secondary to inflammatory, infectious, malignant, or autoimmune processes within the pericardium.3 The fluid may be serious, serofibrinous, serosanguineous or chylous.2
Signs and symptoms of pericardial effusion include chest pain, pressure or discomfort, light-headedness or syncope, palpitations, cough, dyspnoea, hoarseness, anxiety and confusion, and hiccoughs.3 Examination findings in patients with pericardial effusion include the classic Beck triad of pericardial tamponade: hypotension, muffled heart sounds and jugular venous distention. Other examination findings include pulsus paradoxus, pericardial friction rub, tachycardia, hepatojugular reflux, tachypnoea, decreased breath sounds, Ewart sign (dullness to percussion beneath the angle of left scapula), hepatosplenomegaly, weakened peripheral pulses, edema, and cyanosis.3
As an adverse drug reaction it occurs relatively commonly in drug-induced systemic lupus erythematosus; it may also occur as an immunological reaction to a drug.2""" ;
                     rdfs:label "introduction content" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#ischaemicStroke
:ischaemicStroke rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_ICD_code "I63.9" ;
                 OpenPVSignal:has_MedDRA_code 10061256 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Ischaemic stroke" ;
                 rdfs:label "ischaemic stroke" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#labelling
:labelling rdf:type owl:NamedIndividual ,
                    obo:OAE_0001197 ,
                    OpenPVSignal:Structured_Product_Labels_information ,
                    OpenPVSignal:Warning_Information ;
           OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
           OpenPVSignal:refers_to_drug :dasatinib ,
                                       :imatinib ,
                                       :nilotinib ;
           OpenPVSignal:has_content "Moreover, pericardial effusion is reported as an adverse effect in the product information of otherTKIs including imatinib, nilotinib and dasatinib." ;
           rdfs:label "Labelling for TKIs" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#lansoprazole
:lansoprazole rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A02BC03" ,
                                        "A02BC53" ,
                                        "A02BD02" ,
                                        "A02BD03" ,
                                        "A02BD07" ,
                                        "A02BD09" ,
                                        "A02BD10" ;
              rdfs:label "lansoprazole" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#leftVentricularDysfunction
:leftVentricularDysfunction rdf:type owl:NamedIndividual ,
                                     OpenPVSignal:Adverse_Effect ;
                            OpenPVSignal:has_ICD_code "I50.1" ;
                            OpenPVSignal:has_MedDRA_code 10049694 ;
                            OpenPVSignal:has_MedDRA_prefered_term "Left ventricular dysfunction" ;
                            rdfs:label "left ventricular dysfunction" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#lisinopril
:lisinopril rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "C09AA03" ,
                                      "C09BA03" ,
                                      "C09BB03" ,
                                      "C10BX07" ;
            rdfs:label "lisinopril" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#lungNeoplasm
:lungNeoplasm rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Indication ;
              OpenPVSignal:has_ICD_code "C34.90" ;
              OpenPVSignal:has_MedDRA_code 10058467 ;
              OpenPVSignal:has_MedDRA_prefered_term "Lung neoplasm malignant" ;
              rdfs:label "Malignant lung neoplasm" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#magnesium
:magnesium rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_MedDRA_code 10005651 ;
           OpenPVSignal:has_MedDRA_prefered_term "Blood magnesium" ;
           rdfs:label "magnesium" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#magnesiumOxide
:magnesiumOxide rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "A02AA02" ,
                                          "A06AD02" ,
                                          "A12CC10" ;
                rdfs:label "magnesium oxide" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#medicineIneffective
:medicineIneffective rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_MedDRA_code 10013709 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Drug ineffective" ;
                     rdfs:label "medicine ineffective" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#metastaticRenalCellCarcinoma
:metastaticRenalCellCarcinoma rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Indication ;
                              OpenPVSignal:has_ICD_code "C79.00" ;
                              OpenPVSignal:has_MedDRA_code 10050513 ;
                              OpenPVSignal:has_MedDRA_prefered_term "Metastatic renal cell carcinoma" ;
                              rdfs:label "metastatic renal cell carcinoma" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#metoprolol
:metoprolol rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "C07AB02" ,
                                      "C07AB52" ,
                                      "C07BB02" ,
                                      "C07BB52" ,
                                      "C07CB02" ,
                                      "C07FB02" ;
            rdfs:label "metoprolol" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#mirtazapine
:mirtazapine rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "N06AX11" ;
             rdfs:label "mirtazapine" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#moxifloxacin
:moxifloxacin rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "J01MA14" ,
                                        "S01AE07" ;
              rdfs:label "moxifloxacin" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#multipleOrganFailure
:multipleOrganFailure rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Adverse_Effect ;
                      OpenPVSignal:has_MedDRA_code 10077361 ;
                      OpenPVSignal:has_MedDRA_prefered_term "Multiple organ dysfunction syndrome" ;
                      rdfs:label "multiple organ failure" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#myalgia
:myalgia rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_ICD_code "M79.1" ;
         OpenPVSignal:has_MedDRA_code 10028411 ;
         OpenPVSignal:has_MedDRA_prefered_term "Myalgia" ;
         rdfs:label "myalgia" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#myocardialInfarction
:myocardialInfarction rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Adverse_Effect ;
                      OpenPVSignal:has_ICD_code "I21.9" ;
                      OpenPVSignal:has_MedDRA_code 10028596 ;
                      OpenPVSignal:has_MedDRA_prefered_term "Myocardial infarction" ;
                      rdfs:label "myocardial infarction" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#myocardialIschaemia
:myocardialIschaemia rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "I21.9" ;
                     OpenPVSignal:has_MedDRA_code 10028600 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Myocardial ischaemia" ;
                     rdfs:label "myocardial ischaemia" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#nausea
:nausea rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Adverse_Effect ;
        OpenPVSignal:has_ICD_code "R11" ;
        OpenPVSignal:has_MedDRA_code 10028813 ;
        OpenPVSignal:has_MedDRA_prefered_term "Nausea" ;
        rdfs:label "nausea" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#nilotinib
:nilotinib rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:hasClass :Protein_kinase_inhibitors ;
           OpenPVSignal:has_ATC_code "L01XE08" ;
           rdfs:label "nilotinib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#oedemaGeneralised
:oedemaGeneralised rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ;
                   OpenPVSignal:has_ICD_code "R60.1" ;
                   OpenPVSignal:has_MedDRA_code 10018092 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Generalised oedema" ;
                   rdfs:label "oedema generalised" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#ondansetron
:ondansetron rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "A04AA01" ;
             rdfs:label "ondansetron" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#pain
:pain rdf:type owl:NamedIndividual ,
               OpenPVSignal:Adverse_Effect ;
      OpenPVSignal:has_ICD_code "G89.1" ;
      OpenPVSignal:has_MedDRA_code 10033371 ;
      OpenPVSignal:has_MedDRA_prefered_term "Pain" ;
      rdfs:label "pain" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#pantoprazole
:pantoprazole rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A02BC02" ,
                                        "A02BD04" ,
                                        "A02BD11" ;
              rdfs:label "pantoprazole" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#pazopanib
:pazopanib rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:concerns_indication_for_use :RenalCellCarcinoma ,
                                                    :SoftTissueSarcoma ;
           OpenPVSignal:hasClass :Protein_kinase_inhibitors ;
           OpenPVSignal:has_mechanism :MechanismOfPazopanib ;
           OpenPVSignal:has_ATC_code "L01XE11" ;
           rdfs:label "pazopanib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#pericardialEffusion
:pericardialEffusion rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "I31.3" ;
                     OpenPVSignal:has_MedDRA_code 10034474 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Pericardial effusion" ;
                     rdfs:label "pericardial effusion" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#pleuralEffusion
:pleuralEffusion rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_ICD_code "J90" ;
                 OpenPVSignal:has_MedDRA_code 10035598 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Pleural effusion" ;
                 rdfs:label "pleural effusion" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#pneumonia
:pneumonia rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "J15.8" ;
           OpenPVSignal:has_MedDRA_code 10035664 ;
           OpenPVSignal:has_MedDRA_prefered_term "Pneumonia" ;
           rdfs:label "pneumonia" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#pneumothorax
:pneumothorax rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "J93.9" ;
              OpenPVSignal:has_MedDRA_code 10035759 ;
              OpenPVSignal:has_MedDRA_prefered_term "Pneumothorax" ;
              rdfs:label "pneumothorax" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#pregabalin
:pregabalin rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N03AX16" ;
            rdfs:label "pregabalin" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#prochlorperazine
:prochlorperazine rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Drug ;
                  OpenPVSignal:has_ATC_code "N05AB04" ;
                  rdfs:label "prochlorperazine" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#pulmonaryHemorrhage
:pulmonaryHemorrhage rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "R04.89" ;
                     OpenPVSignal:has_MedDRA_code 10037394 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Pulmonary haemorrhage" ;
                     rdfs:label "pulmonary hemorrhage" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#pvSignal
:pvSignal rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Signal ;
          OpenPVSignal:Free_text_reporting_element :DiscussionAndConclusion ,
                                                   :PericardialEffusion ,
                                                   :ReportsInVigiBase ,
                                                   :SummaryContent ,
                                                   :introductionContent ;
          OpenPVSignal:is_supported_by_individual_case_report :report1 ,
                                                              :report10 ,
                                                              :report11 ,
                                                              :report2 ,
                                                              :report3 ,
                                                              :report4 ,
                                                              :report5 ,
                                                              :report6 ,
                                                              :report7 ,
                                                              :report8 ,
                                                              :report9 ;
          OpenPVSignal:is_supported_by_statistical_entity :IC025ForPazopanibAndPericardialEffusion ,
                                                          :ICForPazopanibAndPericardialEffusion ,
                                                          :ReportsFromGermany ,
                                                          :ReportsFromGreece ,
                                                          :ReportsFromIreland ,
                                                          :ReportsFromSingapore ,
                                                          :ReportsFromUnitedStates ,
                                                          :Reports_with_pericardial_effusion_and_erlotinib ,
                                                          :Reports_with_pericardial_effusion_and_gefitinib ,
                                                          :Reports_with_pericardial_effusion_and_imatinib ,
                                                          :Reports_with_pericardial_effusion_and_nilotinib ,
                                                          :Reports_with_pericardial_effusion_and_sorafenib ,
                                                          :Reports_with_pericardial_effusion_and_sunitinib ,
                                                          :Reports_with_pericardial_effussion_and_dasatinib ,
                                                          :reportsInVigibase ,
                                                          :reportsWithMalignantLungNeoplasm ,
                                                          :reportsWithMetastaticRenalCellCarcinomaAsIndication ,
                                                          :reportsWithNoDuplicates ,
                                                          :reportsWithPazopanibAsTheSuspectDrug ,
                                                          :reportsWithPazopanibBeingAdministeredOrally ,
                                                          :reportsWithPositiveRechallenge ,
                                                          :reportsWithSarcomaAsIndication ,
                                                          :reports_included_abnormal_hepatic_function ,
                                                          :reports_recovered_or_recovering ,
                                                          :reports_with_fatal_outcome ,
                                                          :reports_with_moxifloxacin_as_suspect ,
                                                          :reports_with_no_recovery ,
                                                          :reports_with_time_to_onset_information ,
                                                          <http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reports_including_pleural_effusion,_cardiac_temponade_and_fatigue> ;
          OpenPVSignal:refers_to_drug :pazopanib ;
          OpenPVSignal:refers_to_primary_suspect_drug :pazopanib ;
          OpenPVSignal:refers_to_unconfirmed_adverse_effect :pericardialEffusion ;
          mp:supportedByData :Phase_2_trial ,
                             :TKIsTriggeringPericardialEffusion ,
                             :Warning_information_for_pazopanib ,
                             :Warning_on_the_possibility_of_cardiac_dysfunction ,
                             :labelling ;
          OpenPVSignal:initially_identified_on "01/12/13" ;
          rdfs:label "pv signal" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#qtProlongation
:qtProlongation rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_ICD_code "I45.81" ;
                OpenPVSignal:has_MedDRA_code 10014387 ;
                OpenPVSignal:has_MedDRA_prefered_term "Electrocardiogram QT prolonged" ;
                rdfs:label "qt prolongation" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#ramipril
:ramipril rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_ATC_code "C09AA05" ,
                                    "C09BA05" ,
                                    "C09BB05" ,
                                    "C09BB07" ,
                                    "C10BX04" ,
                                    "C10BX06" ;
          rdfs:label "ramipril" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#renalFailure
:renalFailure rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "N18.9" ;
              OpenPVSignal:has_MedDRA_code 10009119 ;
              OpenPVSignal:has_MedDRA_prefered_term "Chronic renal failure" ;
              rdfs:label "chronic renal failure" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#report1
:report1 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:has_free_text_reporting_element :infoForCase1 ;
         OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
         OpenPVSignal:refers_to_patient :Patient1 ;
         OpenPVSignal:refers_to_primary_suspect_drug :pazopanib ;
         OpenPVSignal:refers_to_outcome_after_action "recovering" ;
         rdfs:label "report 1" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#report10
:report10 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:has_free_text_reporting_element :infoForCase10 ;
          OpenPVSignal:refers_to_adverse_effect :diarrhoea ,
                                                :pericardialEffusion ;
          OpenPVSignal:refers_to_patient :Patient10 ;
          OpenPVSignal:refers_to_primary_suspect_drug :pazopanib ;
          OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
          rdfs:label "report 10" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#report11
:report11 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :myalgia ,
                                                :pericardialEffusion ;
          OpenPVSignal:refers_to_concomitant_drug :glimepiride ,
                                                  :ibuprofen ,
                                                  :pregabalin ;
          OpenPVSignal:refers_to_patient :Patient11 ;
          OpenPVSignal:refers_to_primary_suspect_drug :pazopanib ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "report 11" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#report2
:report2 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
         OpenPVSignal:refers_to_patient :Patient2 ;
         OpenPVSignal:refers_to_primary_suspect_drug :pazopanib ;
         OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
         rdfs:label "report 2" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#report3
:report3 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :cardiacTamponade ,
                                               :hepaticEnzymesIncreased ,
                                               :medicineIneffective ,
                                               :pericardialEffusion ;
         OpenPVSignal:refers_to_patient :Patient3 ;
         OpenPVSignal:refers_to_primary_suspect_drug :pazopanib ;
         OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
         rdfs:label "report 3" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#report4
:report4 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:has_free_text_reporting_element :infoForCase4 ;
         OpenPVSignal:refers_to_adverse_effect :cardiacTamponade ,
                                               :cardiomegaly ,
                                               :fatigue ,
                                               :hepaticFailure ,
                                               :hepaticFunctionAbnormal ,
                                               :hepatorenalSyndrome ,
                                               :multipleOrganFailure ,
                                               :pericardialEffusion ,
                                               :pleuralEffusion ,
                                               :pneumonia ,
                                               :renalFailure ;
         OpenPVSignal:refers_to_concomitant_drug :moxifloxacin ;
         OpenPVSignal:refers_to_patient :Patient4 ;
         OpenPVSignal:refers_to_primary_suspect_drug :pazopanib ;
         OpenPVSignal:refers_to_secondary_suspect_drug :moxifloxacin ;
         OpenPVSignal:refers_to_outcome_after_action "irrelevant death" ;
         rdfs:label "report 4" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#report5
:report5 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :effusion ,
                                               :hepaticFunctionAbnormal ,
                                               :oedemaGeneralised ,
                                               :pericardialEffusion ,
                                               :pleuralEffusion ,
                                               :serositis ;
         OpenPVSignal:refers_to_concomitant_drug :amlodipine ,
                                                 :dexamethasone ,
                                                 :lansoprazole ;
         OpenPVSignal:refers_to_patient :Patient5 ;
         OpenPVSignal:refers_to_primary_suspect_drug :pazopanib ;
         OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
         OpenPVSignal:refers_to_rechallenge_outcome "positive rechallenge - condition appeared again" ;
         rdfs:label "report 5" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#report6
:report6 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :fatigue ,
                                               :hypotension ,
                                               :pericardialEffusion ;
         OpenPVSignal:refers_to_concomitant_drug :carvedilol ,
                                                 :pantoprazole ,
                                                 :ramipril ,
                                                 :torasemide ;
         OpenPVSignal:refers_to_patient :Patient6 ;
         OpenPVSignal:refers_to_primary_suspect_drug :pazopanib ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "report 6" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#report7
:report7 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :diseaseRecurrence ,
                                               :pericardialEffusion ;
         OpenPVSignal:refers_to_concomitant_drug :amlodipine ,
                                                 :docusate ,
                                                 :hydromorphone ,
                                                 :ibuprofen ,
                                                 :lisinopril ,
                                                 :magnesium ,
                                                 :metoprolol ,
                                                 :mirtazapine ,
                                                 :ondansetron ,
                                                 :prochlorperazine ,
                                                 :vitaminsNos ;
         OpenPVSignal:refers_to_patient :Patient7 ;
         OpenPVSignal:refers_to_primary_suspect_drug :pazopanib ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "report 7" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#report8
:report8 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
         OpenPVSignal:refers_to_patient :Patient8 ;
         OpenPVSignal:refers_to_primary_suspect_drug :pazopanib ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "report 8" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#report9
:report9 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
         OpenPVSignal:refers_to_concomitant_drug :amlodipine ,
                                                 :magnesiumOxide ,
                                                 :mirtazapine ,
                                                 :ondansetron ,
                                                 :prochlorperazine ,
                                                 :vitaminsNos ;
         OpenPVSignal:refers_to_patient :Patient9 ;
         OpenPVSignal:refers_to_primary_suspect_drug :pazopanib ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "report 9" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reportsInVigibase
:reportsInVigibase rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Reports_group ;
                   OpenPVSignal:refers_to_adverse_effect :pericardialEffusion ;
                   OpenPVSignal:refers_to_drug :pazopanib ;
                   OpenPVSignal:has_count 11 ;
                   OpenPVSignal:refers_to_database "WHO Vigibase" ;
                   rdfs:label "Overall reports in vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reportsWithMalignantLungNeoplasm
:reportsWithMalignantLungNeoplasm rdf:type owl:NamedIndividual ,
                                           OpenPVSignal:Reports_group ;
                                  OpenPVSignal:concerns_indication_for_use :lungNeoplasm ;
                                  OpenPVSignal:is_subgroup_of :reportsWithNoDuplicates ;
                                  OpenPVSignal:has_count 1 ;
                                  OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                  rdfs:label "reports with malignant lung neoplasm" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reportsWithMetastaticRenalCellCarcinomaAsIndication
:reportsWithMetastaticRenalCellCarcinomaAsIndication rdf:type owl:NamedIndividual ,
                                                              OpenPVSignal:Reports_group ;
                                                     OpenPVSignal:concerns_indication_for_use :metastaticRenalCellCarcinoma ;
                                                     OpenPVSignal:is_subgroup_of :reportsWithNoDuplicates ;
                                                     OpenPVSignal:has_count 3 ;
                                                     OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                     rdfs:label "reports with metastatic renal cell carcinoma as indication" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reportsWithNoDuplicates
:reportsWithNoDuplicates rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Reports_group ;
                         OpenPVSignal:is_subgroup_of :reportsInVigibase ;
                         OpenPVSignal:has_count 9 ;
                         OpenPVSignal:has_count_of_men 4 ;
                         OpenPVSignal:has_count_of_women 5 ;
                         OpenPVSignal:has_max_age "81.0"^^xsd:float ;
                         OpenPVSignal:has_median_age "44.0"^^xsd:float ;
                         OpenPVSignal:has_min_age "21.0"^^xsd:float ;
                         OpenPVSignal:refers_to_database "WHO Vigibase" ;
                         rdfs:label "reports with no duplicates" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reportsWithPazopanibAsTheSuspectDrug
:reportsWithPazopanibAsTheSuspectDrug rdf:type owl:NamedIndividual ,
                                               OpenPVSignal:Reports_group ;
                                      OpenPVSignal:is_subgroup_of :reportsWithNoDuplicates ;
                                      OpenPVSignal:refers_to_primary_suspect_drug :pazopanib ;
                                      OpenPVSignal:has_count 8 ;
                                      OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                      rdfs:label "reports with pazopanib as the suspect drug" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reportsWithPazopanibBeingAdministeredOrally
:reportsWithPazopanibBeingAdministeredOrally rdf:type owl:NamedIndividual ,
                                                      OpenPVSignal:Reports_group ;
                                             OpenPVSignal:is_related_with_drug_intake :Oral_administration ;
                                             OpenPVSignal:is_subgroup_of :reportsWithNoDuplicates ;
                                             OpenPVSignal:has_count 8 ;
                                             OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                             rdfs:label "reports with pazopanib being administered orally" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reportsWithPositiveRechallenge
:reportsWithPositiveRechallenge rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Reports_group ;
                                OpenPVSignal:is_subgroup_of :reportsWithNoDuplicates ;
                                OpenPVSignal:has_count 2 ;
                                OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                OpenPVSignal:refers_to_rechallenge_outcome "positive rechallenge - condition appeared again" ;
                                rdfs:label "reports with positive rechallenge" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reportsWithSarcomaAsIndication
:reportsWithSarcomaAsIndication rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Reports_group ;
                                OpenPVSignal:concerns_indication_for_use :sarcoma ;
                                OpenPVSignal:is_subgroup_of :reportsWithNoDuplicates ;
                                OpenPVSignal:has_count 3 ;
                                OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                rdfs:label "reports with sarcoma as indication" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reports_included_abnormal_hepatic_function
:reports_included_abnormal_hepatic_function rdf:type owl:NamedIndividual ,
                                                     OpenPVSignal:Reports_group ;
                                            OpenPVSignal:is_subgroup_of :reportsWithNoDuplicates ;
                                            OpenPVSignal:refers_to_adverse_effect :abnormalHepaticFunction ;
                                            OpenPVSignal:has_count 3 ;
                                            OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                            rdfs:label "reports including abnormal hepatic function" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reports_recovered_or_recovering
:reports_recovered_or_recovering rdf:type owl:NamedIndividual ,
                                          OpenPVSignal:Reports_group ;
                                 OpenPVSignal:is_subgroup_of :reportsWithNoDuplicates ;
                                 OpenPVSignal:has_count 4 ;
                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                 OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
                                 OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
                                 rdfs:label "reports with recovered or recovering" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reports_with_fatal_outcome
:reports_with_fatal_outcome rdf:type owl:NamedIndividual ,
                                     OpenPVSignal:Reports_group ;
                            OpenPVSignal:is_subgroup_of :reportsWithNoDuplicates ;
                            OpenPVSignal:has_count 1 ;
                            OpenPVSignal:refers_to_database "WHO Vigibase" ;
                            OpenPVSignal:refers_to_dechallenge_outcome "unknown" ;
                            OpenPVSignal:refers_to_outcome_after_action "irrelevant death" ;
                            rdfs:label "reports with fatal outcome" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reports_with_moxifloxacin_as_suspect
:reports_with_moxifloxacin_as_suspect rdf:type owl:NamedIndividual ,
                                               OpenPVSignal:Reports_group ;
                                      OpenPVSignal:is_subgroup_of :reportsWithNoDuplicates ;
                                      OpenPVSignal:refers_to_secondary_suspect_drug :moxifloxacin ;
                                      OpenPVSignal:has_count 1 ;
                                      OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                      rdfs:label "reports with moxifloxacin as suspect" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reports_with_no_recovery
:reports_with_no_recovery rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Reports_group ;
                          OpenPVSignal:is_subgroup_of :reportsWithNoDuplicates ;
                          OpenPVSignal:has_count 2 ;
                          OpenPVSignal:refers_to_database "WHO Vigibase" ;
                          OpenPVSignal:refers_to_dechallenge_outcome "negative - condition still applied" ;
                          OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
                          rdfs:label "reports with no recovery" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reports_with_time_to_onset_information
:reports_with_time_to_onset_information rdf:type owl:NamedIndividual ,
                                                 OpenPVSignal:Reports_group ;
                                        OpenPVSignal:is_subgroup_of :reportsWithNoDuplicates ;
                                        OpenPVSignal:time_to_onset :time_to_onset ;
                                        OpenPVSignal:has_count 6 ;
                                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                        rdfs:label "reports with time to onset information" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#sarcoma
:sarcoma rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Indication ;
         OpenPVSignal:has_MedDRA_code 10039491 ;
         OpenPVSignal:has_MedDRA_prefered_term "Sarcoma" ;
         rdfs:label "Sarcoma" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#serositis
:serositis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "K35.3" ;
           OpenPVSignal:has_MedDRA_code 10058556 ;
           OpenPVSignal:has_MedDRA_prefered_term "Serositis" ;
           rdfs:label "serositis" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#skinHypopigmentation
:skinHypopigmentation rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Adverse_Effect ;
                      OpenPVSignal:has_ICD_code "L81.9" ;
                      OpenPVSignal:has_MedDRA_code 10040868 ;
                      OpenPVSignal:has_MedDRA_prefered_term "Skin hypopigmentation" ;
                      rdfs:label "skin hypopigmentation" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#sorafenib
:sorafenib rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "L01XE05" ;
           rdfs:label "sorafenib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#stomatitis
:stomatitis rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_ICD_code "K12" ;
            OpenPVSignal:has_MedDRA_code 10042128 ;
            OpenPVSignal:has_MedDRA_prefered_term "Stomatitis" ;
            rdfs:label "stomatitis" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#sunitinib
:sunitinib rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "L01XE04" ;
           rdfs:label "sunitinib" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#time_to_onset
:time_to_onset rdf:type owl:NamedIndividual ,
                        <http://www.w3.org/2006/time#DurationDescription> ;
               OpenPVSignal:has_content "Time to onset was reported in six of the reports. It ranged from eight weeks to six months with a median of four months in five cases" ;
               <http://www.w3.org/2006/time#nominalPosition> "weeks" ;
               <http://www.w3.org/2006/time#numericDuration> 24 ;
               <http://www.w3.org/2006/time#numericPosition> 8 ;
               rdfs:label "time to onset" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#torasemide
:torasemide rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "C03CA04" ;
            rdfs:label "torasemide" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#transientIschaemicAttack
:transientIschaemicAttack rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Adverse_Effect ;
                          OpenPVSignal:has_ICD_code "G45.9" ;
                          OpenPVSignal:has_MedDRA_code 10044390 ;
                          OpenPVSignal:has_MedDRA_prefered_term "Transient ischaemic attack" ;
                          rdfs:label "transient ischaemic attack" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#undifferentiatedNasopharyngealCarcinoma
:undifferentiatedNasopharyngealCarcinoma rdf:type owl:NamedIndividual ,
                                                  OpenPVSignal:Indication ;
                                         OpenPVSignal:has_ICD_code "C11.9" ;
                                         OpenPVSignal:has_MedDRA_code 10073328 ;
                                         OpenPVSignal:has_MedDRA_prefered_term "Undifferentiated nasopharyngeal carcinoma" ;
                                         rdfs:label "undifferentiated nasopharyngeal carcinoma" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#venousThromboembolicEvents
:venousThromboembolicEvents rdf:type owl:NamedIndividual ,
                                     OpenPVSignal:Adverse_Effect ;
                            OpenPVSignal:has_MedDRA_code 10066899 ;
                            OpenPVSignal:has_MedDRA_prefered_term "Venous thromboembolism" ;
                            rdfs:label "venous thromboembolic events" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#vitaminsNos
:vitaminsNos rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "A11" ;
             rdfs:label "vitamins nos" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#vomiting
:vomiting rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "R11" ,
                                    "R1110" ;
          OpenPVSignal:has_MedDRA_code 10047700 ;
          OpenPVSignal:has_MedDRA_prefered_term "Vomiting" ;
          rdfs:label "vomiting" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#weightDecreased
:weightDecreased rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_ICD_code "R63.4" ;
                 OpenPVSignal:has_MedDRA_code 10047895 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Weight decreased" ;
                 rdfs:label "weight decreased" .


###  http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reports_including_pleural_effusion,_cardiac_temponade_and_fatigue
<http://purl.org/OpenPVSignal/Signals/2013_6_pazopanib_pericardial_effusion#reports_including_pleural_effusion,_cardiac_temponade_and_fatigue> rdf:type owl:NamedIndividual ,
                                                                                                                                                        OpenPVSignal:Reports_group ;
                                                                                                                                               OpenPVSignal:is_subgroup_of :reportsWithNoDuplicates ;
                                                                                                                                               OpenPVSignal:refers_to_adverse_effect :cardiacTamponade ,
                                                                                                                                                                                     :fatigue ,
                                                                                                                                                                                     :pleuralEffusion ;
                                                                                                                                               OpenPVSignal:has_count 2 ;
                                                                                                                                               OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                                                                                                               rdfs:label "reports including pleural effusion, cardiac temponade and fatigue" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
